Armata Submits Phase 3 Protocol, Advances Manufacturing
The company completed four engineering runs ahead of planned clinical-material production.
Armata Pharmaceuticals (ARMP), a clinical-stage biotechnology company, submitted the complete Phase 3 superiority protocol for AP-SA02 and responses addressing all clinical, manufacturing, and regulatory feedback from the Food and Drug Administration.
The submission marked a shift from the general Phase 3 preparations Armata described in May to a defined regulatory package for the study. The company continues to target the second half of 2026 for the trial’s start, maintaining the timing given in May and an earlier July update.
Manufacturing work advanced alongside the regulatory process. Armata completed four AP-SA02 engineering runs and production of Phase 3 clinical-trial material is the next planned step.
The company also added $2.5 million in Defense Department funding to support Phase 3 preparation and readiness. The increase brought cumulative funding under the award to $28.7 million.
Armata’s next milestones center on producing the trial material and starting the superiority study. The planned launch remains in the second half despite the newly completed regulatory and manufacturing steps.
The company also promoted David House to chief financial officer. House had served as senior vice president of finance and principal financial officer since August 2024.